114 results
6-K
EX-5.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
beyond the matters expressly so stated. This opinion letter is given as of the date hereof and we do not undertake any liability or responsibility
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
Adverse Effect.
(q) Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass … in a global security. We and the trustee have no responsibility for any aspect of the depositary’s actions or for its records of ownership interests
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have … been the responsibility of our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms
F-3
74tqyrfzyw wom1suuo
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
wljwb4wh82mgb vcp9x
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
2578eoxf7l eiq
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
tddsasw3gxpkpd tbc7g
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
xw84ekx37nd 7g8z46uo
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
477ckhbqqdbl
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-5.2
9872 2h6x7
21 Sep 22
Current report (foreign)
8:00am
6-K
EX-10.1
pybaxa
21 Sep 22
Current report (foreign)
8:00am
424B5
j7fcbr2860zibg2u k8
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
d0md1zuz
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-10.1
e8pfl6dmv9oj h89s
3 Sep 21
Current report (foreign)
4:30pm
424B5
b42fu3
3 Sep 21
Prospectus supplement for primary offering
4:29pm